Abstract
We have previously labeled cyclic RGD peptide c(RGDyK) with fluorine-18 through conjugation labeling via a prosthetic 4-[18F]fluorobenzoyl moiety and applied this [18F]FB-RGD radiotracer for alphav-integrin expression imaging in different preclinical tumor models with good tumor-to-background contrast. However, the unfavorable hepatobiliary excretion and rapid tumor washout rate of this tracer limit its potential clinical applications. The aims of this study were to modify the [18F]FB-RGD tracer by inserting a heterobifunctional poly(ethylene glycol) (PEG, M.W. =3,400) between the 18F radiolabel and the RGD moiety and to test this [18F]FB-PEG-RGD tracer for brain tumor targeting and in vivo kinetics. [18F]FB-PEG-RGD was prepared by coupling the RGD-PEG conjugate with N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) under slightly basic conditions (pH=8.5). The radiochemical yield was about 20-30% based on the active ester [18F]SFB, and specific activity was over 100 GBq/micromol. This tracer had fast blood clearance, rapid and high tumor uptake in the subcutaneous U87MG glioblastoma model (5.2+/-0.5%ID/g at 30 min p.i.). Moderately rapid tumor washout was observed, with the activity accumulation decreased to 2.2+/-0.4%ID/g at 4 h p.i. MicroPET and autoradiography imaging showed a very high tumor-to-background ratio and limited activity accumulation in the liver, kidneys and intestinal tracts. U87MG tumor implanted into the mouse forebrain was well visualized with [18F]FB-PEG-RGD. Although uptake in the orthotopic tumor was significantly lower (P<0.01) than in the subcutaneous tumor, the maximum tumor-to-brain ratio still reached 5.0+/-0.6 due to low normal brain background. The results of H&E staining post mortem agreed with the anatomical information obtained from non-invasive microPET imaging. In conclusion, PEGylation suitably modifies the physiological behavior of the RGD peptide. [18F]FB-PEG-RGD gave improved tumor retention and in vivo kinetics compared with [18F]FB-RGD.
MeSH Terms
Animals
Brain/blood supply,diagnostic imaging,metabolism
Brain Neoplasms/diagnostic imaging,metabolism
Female
Glioblastoma/diagnostic imaging,metabolism
Metabolic Clearance Rate
Mice
Mice, Nude
Neovascularization, Pathologic/diagnostic imaging,metabolism
Organ Specificity
Peptides, Cyclic/pharmacokinetics
Polyethylene Glycols/pharmacokinetics
Positron-Emission Tomography/methods
Radiopharmaceuticals/pharmacokinetics
Tissue Distribution
Whole-Body Counting
Chemicals
4-fluorobenzoyl-polyethylene glycol-cyclo(arginyl-glycyl-aspartyl-tyrosyl-lysyl)
Peptides, Cyclic
Radiopharmaceuticals
Polyethylene Glycols
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Chen Xiaoyuan
PET Imaging Science Center, Department of Radiology, University of Southern California Keck School of Medicine, 1510 San Pablo St., Suite 350, CA 90033, Los Angeles, USA.
Park Ryan
Hou Yingping
Khankaldyyan Vazgen
Gonzales-Gomez Ignacio
Tohme Michel
Bading James R
Laug Walter E
Conti Peter S
References (33)
33 references, click to expand
-
Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting.
Cancer Biother Radiopharm. 2002 Dec;17 (6):641-6
PMID: 12537667
-
Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta3 integrin related tumor imaging.
Nucl Med Biol. 2003 Jan;30(1):1-9
PMID: 12493537
-
Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.
Int J Cancer. 2000 Aug 20;90(4):186-98
PMID: 10993959
-
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
J Nucl Med. 1999 Jun;40(6):1061-71
PMID: 10452325
-
A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation.
Nucl Med Biol. 1996 Apr;23(3):365-72
PMID: 8782249
-
Angiogenesis in brain tumors.
Microsc Res Tech. 2003 Feb 1;60(2):225-30
PMID: 12539176
-
Chemistry for peptide and protein PEGylation.
Adv Drug Deliv Rev. 2002 Jun 17;54(4):459-76
PMID: 12052709
-
Molecular epidemiology of glioblastoma.
Cancer J. 2003 Mar-Apr;9(2):99-106
PMID: 12784875
-
Cytostatic Agents in the Management of Malignant Gliomas.
Cancer Control. 1998 Mar;5(2):150-162
PMID: 10761026
-
Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging.
Nat Med. 1998 May;4(5):623-6
PMID: 9585240
-
Effect of pegylation on pharmaceuticals.
Nat Rev Drug Discov. 2003 Mar;2(3):214-21
PMID: 12612647
-
Labeling proteins at high specific activity using N-succinimidyl 4-[18F](fluoromethyl) benzoate.
Appl Radiat Isot. 1997 Feb;48(2):169-73
PMID: 9219343
-
alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.
Int J Cancer. 2002 Apr 10;98(5):690-7
PMID: 11920637
-
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Cancer Res. 2002 Nov 1;62(21):6146-51
PMID: 12414640
-
Glial tumors--new approaches in chemotherapy.
J Neurosci Nurs. 2002 Dec;34(6):326-30
PMID: 12506816
-
The uses and properties of PEG-linked proteins.
Crit Rev Ther Drug Carrier Syst. 1992;9(3-4):249-304
PMID: 1458545
-
Current and future strategies for the treatment of malignant brain tumors.
Pharmacol Ther. 2003 Apr;98(1):71-108
PMID: 12667889
-
Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET.
Nucl Med Biol. 1995 Aug;22(6):783-9
PMID: 8535339
-
Targeted molecular therapy of GBM.
Brain Pathol. 2003 Jan;13(1):52-61
PMID: 12580545
-
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography.
Cancer Res. 2001 Mar 1;61(5):1781-5
PMID: 11280722
-
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.
Neurosurgery. 2001 Jan;48(1):151-7
PMID: 11152340
-
Anti-angiogenic agents for the treatment of brain tumors.
Neuroimaging Clin N Am. 2002 Nov;12(4):477-99
PMID: 12687907
-
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
J Nucl Med. 2001 Feb;42(2):326-36
PMID: 11216533
-
In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging.
Bioconjug Chem. 2002 May-Jun;13(3):561-70
PMID: 12009947
-
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
J Med Chem. 1999 Aug 12;42(16):3033-40
PMID: 10447947
-
Role of angiogenesis in tumor growth and metastasis.
Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
PMID: 12516034
-
Fluorine-18 labeling of proteins.
J Nucl Med. 1987 Apr;28(4):462-70
PMID: 3494825
-
New perspectives in cell adhesion: RGD and integrins.
Science. 1987 Oct 23;238(4826):491-7
PMID: 2821619
-
Pegylation: a novel process for modifying pharmacokinetics.
Clin Pharmacokinet. 2001;40(7):539-51
PMID: 11510630
-
Positron emission tomography imaging of brain tumors.
Neuroimaging Clin N Am. 2002 Nov;12 (4):615-26
PMID: 12687915
-
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation.
Nucl Med Biol. 2004 Jan;31(1):11-9
PMID: 14741566
-
Anti-angiogenic therapy: rationale, challenges and clinical studies.
Angiogenesis. 2002;5(4):237-56
PMID: 12906317
-
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.
Nat Med. 1998 Nov;4(11):1334-6
PMID: 9809561